Pekin Hardy Strauss, Inc. Abb Vie Inc. Transaction History

Pekin Hardy Strauss, Inc.

$749 Million
Q3 2024

A detailed history of Pekin Hardy Strauss, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Pekin Hardy Strauss, Inc. holds 34,591 shares of ABBV stock, worth $5.93 Million. This represents 0.91% of its overall portfolio holdings.

Number of Shares

34,591

Previous 34,935 0.98%

Holding current value

$5.93 Million

Previous $5.99 Million 14.0%

% of portfolio

0.91%

Previous 0.86%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$163.84 - $199.33 $56,360 - $68,569	-344 Reduced 0.98%	34,591 $6.83 Million
Q2 2024 Aug 09, 2024	SELL	$154.79 - $180.76 $46,127 - $53,866	-298 Reduced 0.85%	34,935 $5.99 Million
Q1 2024 May 02, 2024	SELL	$159.82 - $182.1 $47,466 - $54,083	-297 Reduced 0.84%	35,233 $6.42 Million
Q4 2023 Feb 05, 2024	BUY	$137.6 - $154.97 $48,710 - $54,859	354 Added 1.01%	35,530 $5.51 Million
Q3 2023 Nov 07, 2023	SELL	$133.59 - $154.65 $70,401 - $81,500	-527 Reduced 1.48%	35,176 $5.24 Million
Q2 2023 Aug 08, 2023	SELL	$132.51 - $164.9 $174,648 - $217,338	-1,318 Reduced 3.56%	35,703 $4.81 Million
Q1 2023 May 08, 2023	SELL	$144.61 - $166.54 $52,059 - $59,954	-360 Reduced 0.96%	37,021 $5.9 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $49,238 - $59,049	-356 Reduced 0.94%	37,381 $6.04 Million
Q3 2022 Nov 09, 2022	SELL	$134.21 - $153.93 $36,505 - $41,868	-272 Reduced 0.72%	37,737 $5.07 Million
Q2 2022 Aug 05, 2022	BUY	$137.62 - $174.96 $27,936 - $35,516	203 Added 0.54%	38,009 $5.82 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $178,964 - $222,045	-1,356 Reduced 3.46%	37,806 $6.13 Million
Q4 2021 Feb 08, 2022	BUY	$107.43 - $135.93 $4,189 - $5,301	39 Added 0.1%	39,162 $5.3 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $38,516 - $43,722	-362 Reduced 0.92%	39,123 $4.22 Million
Q2 2021 Aug 12, 2021	SELL	$105.21 - $117.21 $631 - $703	-6 Reduced 0.02%	39,485 $4.45 Million
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $17,186 - $18,920	-168 Reduced 0.42%	39,491 $4.27 Million
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $142,064 - $191,802	1,765 Added 4.66%	39,659 $4.25 Million
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $29,037 - $34,080	338 Added 0.9%	37,894 $3.32 Million
Q2 2020 Aug 10, 2020	BUY	$73.37 - $98.18 $118,419 - $158,462	1,614 Added 4.49%	37,556 $3.69 Million
Q1 2020 May 11, 2020	SELL	$64.5 - $97.79 $150,091 - $227,557	-2,327 Reduced 6.08%	35,942 $2.74 Million
Q4 2019 Feb 12, 2020	BUY	$72.13 - $90.25 $92,975 - $116,332	1,289 Added 3.49%	38,269 $3.39 Million
Q3 2019 Nov 12, 2019	SELL	$62.98 - $75.72 $126,967 - $152,651	-2,016 Reduced 5.17%	36,980 $2.8 Million
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $200,056 - $255,719	3,045 Added 8.47%	38,996 $2.84 Million
Q1 2019 May 14, 2019	BUY	$77.14 - $90.79 $15,659 - $18,430	203 Added 0.57%	35,951 $2.9 Million
Q4 2018 Feb 12, 2019	SELL	$77.85 - $96.01 $34,876 - $43,012	-448 Reduced 1.24%	35,748 $3.3 Million
Q3 2018 Nov 02, 2018	SELL	$88.91 - $98.84 $103,669 - $115,247	-1,166 Reduced 3.12%	36,196 $3.42 Million
Q2 2018 Aug 03, 2018	SELL	$89.78 - $106.23 $109,711 - $129,813	-1,222 Reduced 3.17%	37,362 $3.46 Million
Q1 2018 May 01, 2018	SELL	$92.01 - $123.21 $1.1 Million - $1.47 Million	-11,939 Reduced 23.63%	38,584 $0
Q4 2017 Feb 02, 2018	SELL	$89.56 - $98.21 $147,594 - $161,850	-1,648 Reduced 3.16%	50,523 $0
Q3 2017 Nov 03, 2017	BUY	$69.85 - $89.22 $3.64 Million - $4.65 Million	52,171	52,171 $4.64 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pekin Hardy Strauss, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pekin Hardy Strauss, Inc. with notifications on news.

Account

Pekin Hardy Strauss, Inc. Abb Vie Inc. Transaction History